DDIT3 and prostate cancer: Although a single study reported an increase in CHOP expression in response to the natural naphthoquinone plumbagin in the treatment of prostate cancer (Huang et al., 2018), this discrepancy could be due to the different pathophysiology of tissue and disease and the very different chemical structure of the naphthoquinone used in this study compared to UTA77.